The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumorsPLN-101095 accelerated ...

Doctors in New Delhi have achieved two successful live births by treating severe Asherman's Syndrome with umbilical cord-derived stem cells. The pioneering procedure offers new hope to women suffering ...

NorthStrive Fund II LP ("NorthStrive Fund", "we", "our" or "us"), a subsidiary of NorthStrive Companies Inc., headquartered in Newport Beach, California, is a significant shareholder of Bluejay ...

Mezigdomide plus carfilzomib and dexamethasone improves progression free survival in patients with relapsed or refractory multiple myeloma. Positive interim results were announced from a phase 3 trial ...

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

Johnson & Johnson JNJ announced that it has submitted a type II variation application to the European Medicines Agency (EMA) seeking approval for the expanded use of Tecvayli (teclistamab). The ...

Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026U.S. Food and Drug ...

A two-step approach pooled indication-specific response rates, then generated naïve odds ratios via random-effects models, reflecting limited head-to-head evidence across BTK inhibitors. Across ...